CEimpact Podcast

Opioids are always in the news for adverse reactions and poor outcomes. Two opioids - tramadol and codeine - are often left out of the fey as potential alternatives. Yet, these medications are not without adverse events. A recent study evaluated the mortality and safety differences in tramadol and codeine.

Redeem your CPE or CME credit here!

• Pharmacist members
• CME

Need a membership?

• Join for CPE Credit
• Join for CME Credit 

References and resources:

Xie J, Strauss VY, Martinez-Laguna D, et al. Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes. JAMA. 2021;326(15):1504–1515. doi:10.1001/jama.2021.15255

Continuing Education Information:

Learning Objectives:

1. Describe the risks associated with tramadol compared to codeine
2. Discuss the role of tramadol in managing a patient's pain

Dr. Wall is a member of the Janssen Speaker's Bureau.

0.05 CEU | 0.5 Hrs

ACPE UAN: 0107-0000-22-097-H01-P

Initial release date: 03/7/22

Expiration date: 03/7/2023

Additional CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram

Part 2 of this special two-part series takes a deep dive into the top clinical medicine and healthcare issues that have been true GameChangers this past year. Join us as Geoff Wall and Jake Galdo discuss the latest in practice trends, policy changes, guideline updates, new laws, and much more. Did you miss Part 1? If so, be sure to check out GameChangers Episode #308 for more important GameChangers!

Host:
John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad, Inc.

Dr. Galdo serves in an advisory role and as a member of a speaker’s bureau for Novo Nordisk.

Guest:
Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Dr. Wall is a member of a speaker’s bureau for Janssen.

References and Resources
Dr. Wall prepared slides for this episode with all references and citations, click HERE to download.

Already a member? Redeem your CPE or CME credit here

• Pharmacist Members
•  CME
• Pharmacy Technicians

Need a membership?

• Join for CPE Credit
• Join for CME Credit

This episode was made possible by the PharmaCE Expo and the Iowa Pharmacy Association. Register for this year's PharmaCE Expo May 17-18 at the Hilton Des Moines Downtown here! Pharmacists and pharmacy technicians who register receive CPE for this course AND have the opportunity to receive over 14 hours of CE for pharmacists and pharmacy technicians. 

CE Information

Learning Objectives – Pharmacists and Prescribers

Upon successful completion of this knowledge-based CPE activity, participants should be able to:

1. Classify "Gamechangers" by how they affect practice settings.
2. Discuss the selection of a "Gamechanger" topic and how it will impact the provision of patient care.
3. Describe possible solutions to clinical problems listed throughout the presentation.
4. Assess the clinical trials used to support the content for this presentation.
5. Apply the information presented to influence patient care and outcomes at your specific practice site.

0.075 CEU/0.75 hr
UAN: 0107-0000-22-116-H01-P

Learning Objectives – Pharmacy Technicians

Upon successful completion of this knowledge-based CPE activity, participants should be able to:

1. Classify "Gamechangers" by how they affect practice settings.
2. Discuss the selection of a "Gamechanger" topic and how it will impact the provision of patient care.
3. Describe opportunities for the advancement of pharmacy technician roles based on information presented.
4. Identify the clinical trials used to support the content for this presentation.
5. Apply the information presented to influence patient care and at your specific practice site.

0.075 CEU/0.75 hr
UAN: 0107-0000-22-116-H01-T
Initial release date: 02/21/2022
Planned expiration date: 02/21/2022
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

It's easy to focus on the development of clinical skills in our pharmacy learners, but what is our responsibility as preceptors for their personal and professional development? Join us for this episode where Jake Galdo and Josh Kinsey share their thoughts on the importance of developing the whole student, and how this investment will positively impact pharmacy practice. We'll touch on everything from the importance of creating safe space to counseling students on the importance of personal finance.

Host:
Kathy Schott, PhD
CEimpact

Guests:
Dr. John (Jake) A. Galdo, PharmD, MBA, BCPS, BCGP
Curriculum Development, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad

Dr. Joshua Davis Kinsey, PharmD
Manager, Client Services
CEimpact

Click here to access the course and claim CE for listening to the episode.

CE Information

At the end of this course, preceptors will be able to:

1. Discuss the importance of supporting students in their personal and professional development

2. Describe strategies to engage students in conversations around career planning, fiscal responsibility, work-life balance, and overall well-being.

UAN: 0107-0000-25-018-H99-P
Release Date: 03/24/2025
Expiration Date: 03/24/2028
The speakers have no relevant financial relationships with ineligible companies to disclose. 

Want more information on this topic? If you are looking for some more specific guidance relative to career mentoring, check out courses on helping students get ready for interviews, how to evaluate a CV, and writing letters of recommendation:

• Helping Your Students Get Ready for Interviews
• How to Evaluate a CV
• Writing Letters of Recommendation that Matter

If you are looking for some guidance on how you approach mentoring and how you might further develop your skills in that aspect of precepting, check out the Eleven Habits of Highlight Effective Preceptors. This course explores the skills and behaviors demonstrated by an effective mentor and will put you on a path toward personal growth in mentoring pharmacy learners.

The Eleven Habits of Highly Effective Preceptors

Follow CEimpact on Social Media:
LinkedIn
Instagram

Part 1 of this special two-part series takes a deep dive into the top clinical medicine and healthcare issues that have been true GameChangers in 2021. Join us as Geoff Wall and Jake Galdo discuss the latest in practice trends, policy changes, guideline updates, new laws, and much more.

Show Segments:
01:38 – SGLT2 Inhibitors in Heart Failure
14:47 – Point of Care Testing
26:32 – Semaglutide for Weight Loss
39:29 – Depo Antipsychotics

John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
Dr. Galdo serves in an advisory role and as a member of a speaker’s bureau for Novo Nordisk.

Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Dr. Wall is a member of a speaker’s bureau for Janssen.

References and Resources
Dr. Wall prepared slides for this episode with all references and citations, click HERE to download.

Redeem your CPE or CME credit

• Pharmacist members
• CME
• Pharmacy Technicians

Need a membership?

• Join for CPE Credit
• Join for CME Credit 

This episode was made possible by the PharmaCE Expo and the Iowa Pharmacy Association. Register for PharmaCE Expo May 17-18 at the Hilton Des Moines Downtown here! Pharmacists and pharmacy technicians who register receive CPE for this course AND have the opportunity to receive over 14 hours of CE.

CE Information
Learning Objectives – Pharmacists and Prescribers
Upon successful completion of this knowledge-based CPE activity, participants should be able to:

 1.     Classify "Gamechangers" by how they affect practice settings.
2.     Discuss the selection of a "Gamechanger" topic and how it will impact the provision of patient care.
3.     Describe possible solutions to clinical problems listed throughout the presentation.
4.     Assess the clinical trials used to support the content for this presentation.
5.     Apply the information presented to influence patient care and outcomes at your specific practice site.
0.075 CEU/0.75 hr
UAN: 0107-0000-22-115-H01-P

Learning Objectives – Pharmacy Technicians
Upon successful completion of this knowledge-based CPE activity, participants should be able to:

1.     Classify "Gamechangers" by how they affect practice settings.
2.     Discuss the selection of a "Gamechanger" topic and how it will impact the provision of patient care.
3.     Describe opportunities for the advancement of pharmacy technician roles based on information presented.
4.     Identify the clinical trials used to support the content for this presentation.
5.     Apply the information presented to influence patient care and at your specific practice site.

0.075 CEU/0.75 hr
UAN: 0107-0000-22-115-H01-T
Initial release date: 02/21/2022
Planned expiration date: 02/21/2022
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Weight gain can impact patient’s quality of life and put them at risk for health complications. While weight loss can be an important factor in a patient’s health, it is equally important that it is done safely and effectively. Listen in as host, Geoff Wall compares the safety and efficacy of semaglutide and liraglutide in weight loss. 

The GameChanger:

• Based on a recent Phase-3 study, semaglutide appears to be more effective in weight loss than liraglutide 
• Semaglutide also appeared to have modest effects on decreasing systolic blood pressure, blood sugar, lipid concentrations, and serum insulin levels
• GLP-1 agonists are expensive medications – patients should be made aware of the of the associated cost as a part of patient centered care 

Show Segments:

00:00 – Introductions

01:10 – GLP-1s Agonist (Semaglutide vs Liraglutide) in Weight Management

10:00 – Change in Body Weight 

12:02 – Secondary Outcomes – Blood Pressure, Blood Sugar, Lipid Concentrations, & Serum Insulin

12:59 – Safety & Side Effects

14:15 – Cost

14:52 – The GameChanger

17:20 – Closing Remarks

Links to Resources:

Effects of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes

How to Claim CE:

CE is available for CEimpact members:

·       Click here to claim CPE Credit 

·       Click here to claim CME Credit 

Need a membership?

• Join for CPE Credit 
•  Join for CME Credit

Continuing Education Information:
Learning Objectives:
1. Describe the inclusion and exclusion criteria of the STEP 8 study
2. Discuss the outcomes of the STEP 8 study

Dr. Wall is a member of the Janssen Speaker's Bureau.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-088-H01-P
Initial release date: 02/14/22
Expiration date: 02/14/2023
Additional CPE & CME details can be found here"

Follow CEimpact on Social Media:
LinkedIn
Instagram

Every January, the American Diabetes Association updates the Standards of Medical Care in Diabetes. The guidelines cover updates from diabetes advocacy to technology changes. Learn what changed and what matters most for individuals with diabetes.

• Time in range was introduced in the 2021 update and is becoming the standard of glycemic targets and control 
• Metformin may not be the first line option for type 2 diabetes – comorbid conditions and cost to the patient should be considered when determining appropriate treatment 
• More data is emerging suggesting the SGLT-2 inhibitors slow progression of diabetic neuropathy, CKD, and other comorbid conditions GLP-1 drugs may also aid in neuropathy
• In older adults with diabetes, the upper threshold of A1c goal of 8.5% may not be as global as originally thought – glycemic targets should be matched with patient status and factors 

00:00 – Introductions

03:25 – Improving Care and Promoting Health

06:07 – Classification of Diabetes

07:55 – Prevention of Diabetes

10:02 – Comprehensive Medication Evaluation 

12:05 – Facilitating Behavior Changes

14:14 – Glycemic Targets & DM Technology 

17:08 – Obesity 

18:15 – Pharmacologic Approach 

24:00 – Cardiovascular Disease

25:26 – Chronic Kidney Disease Management

26:06 – Retinopathy, Neuropathy, & Foot Care

28:15 – Diabetes in Older Adults

29:38 – Closing Remarks 

John (Jake) A. Galdo, PharmD, MBA, BCPS, BCGP Course Content and Developer, CEimpact Pharmacist, Ross Bridge Pharmacy CEO, Seguridad, Inc

Dr. Galdo received his Doctor of Pharmacy and completed PGY-1 Community Pharmacy Residency training from the University of Georgia, earned a Master of Business Administration from Samford University, and is board certified in both pharmacotherapy and geriatrics. Jake Galdo helps lead content and course development at CEimpact. 

Links to Resources:

Standards of Medical Care in Diabetes-2022

Take a deeper dive into glycemic management with Sue Cornell, BS, Pharm.D, CDCES, FAPhA, FADCES: CEimpact

Dr. Cornell currently serves as the associate director of experiential education and professor in the department of pharmacy practice at Midwestern University College of Pharmacy in Downers Gove, Illinois. She is also a certified diabetes care and education specialist. 

How to Claim CE: 

·     Pharmacist

·      CME

Need a membership?

• Join for CPE Credit 
• Join for CME Credit 

Continuing Education Information:
Learning Objectives: 

1. Describe changes to the type 2 diabetes treatment algorithm based on the 2022 guidelines
2. Identify appropriate first-line therapy for persons with diabetes and cardiovascular disease

Dr. Wall is a member of the Janssen Speaker's Bureau.
Dr. Galdo reports no actual or potential conflicts of interest associated with this episode.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-071-H01-P
Initial release date: 02/07/22
Expiration date: 02/07/23
Additional CPE & CME details can be found here"

Follow CEimpact on Social Media:
LinkedIn
Instagram

While HIV treatment has come a long way over the decades, it still faces challenges. Specifically, HIV therapy such as integrase inhibitors have been associated with increased weight gain but the mechanism and extent of which has remained largely unknown. Listen in as Dave Hachey, HIV expert, and Geoff Wall discuss this and how it impacts medication selection when caring for patients with HIV.

The Gamechanger: 

• The risk of weight gain with integrase inhibitor and other potential HIV regimens should be discussed with patients
• Patients’ comorbidities should risk factors should be considered when determining an appropriate treatment regimen
• Studies suggest that the mechanism of weight gain from integrase inhibitors and older agents such as tenofovir alafenamide is different, although more research is needed

Show Segments: 

00:00 – Introductions

04:36 – HIV Treatment & Weight Gain 

07:27 – Integrase Inhibitors vs Tenofovir Alafenamide 

17:12 – The GameChanger

26:22 – Closing Remarks

Guest Bios:

David Hachey, PharmD, AAHIVP Professor Idaho State University

After graduating from the University of Rhode Island, Dr. Hachey completed a residency and fellowship in Family Medicine at Idaho State University. After, he stayed in Idaho and expanded his role with the College of Pharmacy and the Department of Family Medicine. Dr. Hachey has experience within the community setting and has also served as the director of the regional Ryan White HIV Clinic for the last 15-20 years. His vast experience gives him a unique perspective on the challenges pharmacists and patients face in preventing and managing HIV.   

Links to Resources: 

Excess Weight Gain with Integrase Inhibitors and Tenofovir Alafenamide Study

How to Claim CE:

CE is available for CEimpact members. 

• Click here to claim CPE Credit
• Click here to claim  CME Credit

Get a membership:

• Join for CPE Credit 
• Join for CME Credit 

References and resources: 

• Wood B, Huhn G. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?. Open Forum Infectious Diseases, Volume 8, Issue 12, December 2021. https://doi.org/10.1093/ofid/ofab542

Continuing Education Information:

Learning Objectives: 

1. Describe the proposed mechanism for weight gain due to integrase inhibitors
2. Identify co-morbid conditions with HIV that may influence medication selection

Dr. Wall is a member of the Janssen Speaker's Bureau. 
Dr. Hachey reports no actual or potential conflicts of interest associated with this episode.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-070-H01-P
Initial release date: 01/03/22
Expiration date: 01/03/2023
Additional CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram

Failure is universal to the human experience. Grit, or the ability to demonstrate tenacity, perseverance, and resilience in the face of failure is a learned skill. Success requires both. Join us  in a conversation with Dr. Michael Rupp, failure "master", professor, preceptor, and student mentor. We'll discuss the value of failure, as well as the challenges and opportunities we face as teachers and mentors in creating an environment where failure is an option - or even encouraged.

Host:
Kathy Schott, PhD
CEimpact

Guest:
Dr. Michael Rupp, PhD
Professor
Midwestern University - Glendale

Click here to access the course and claim CE for listening to the episode.

Want more information on this topic? Visit this CE course at www.CEimpact.com:

True Grit: Developing a Philosophy of Failure

• Failure may be the single most critical key to student success when balanced with the right structures and supports. And yet, we often expect perfection. Take this course to understand what it means to adopt a "philosophy of failure" and create an environment where pharmacy learners can thrive.

Acknowledgements:
Special thanks to the Northwest Pharmacy Experiential Consortium, who helped conceive the concept for this podcast and assisted it in its launch. Collaboration is one of CEimpact’s core values, and we are grateful for their partnership.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Studies show that opioids are the number one prescribed medication for peripheral neuropathy contrary to evidence suggesting a lack of efficacy. Despite being a common condition for individuals with diabetes, treatment is often non-evidence based, meaning that creating a care plan can be difficult. With this, the American Academy of Neuropathy (AAN) was urged to re-evaluate treatment recommendations for Diabetic Neuropathy Pain (DNP). Listen in as Dr. John Swegle, a pain management expert, and host Geoff Wall discuss the updates on DNP treatment recommendations. 

The GameChanger:

• AAN guidelines reaffirmed that opioids should not be used in the treatment of DNP
• More appropriate treatments for DNP would include gabapentinoids, TCAs, and SNRIs
• SNRI, especially venlafaxine dosing should be targeted to achieve the norepinephrine effects of the drug class
• For patients wishing for natural therapy regimens, gingko may be considered 

Show Segments:

00:00 – Introductions

02:05 – The American Academy of Neuropathy Guideline Update

05:29 – Treating and Controlling Diabetes

06:27 – Comparing Gabapentinoids, Sodium Channel Blockers, SNRIs, Opioids, and TCAs

12:30 – The GameChanger 

19:29 – The American Academy of Neuropathy Recommendations

24:49 – Closing Remarks 

Guest Bios:

John Swegle, PharmD, BCPS, BCACP Clinical Associate Professor University of Iowa College of Pharmacy

John received his PharmD degree from the University of Iowa. He currently is a Clinical Associate Professor with the University of Iowa and clinical pharmacist with the Mercy Family Medicine Residency Program. In addition, he works with Hospice of North Iowa serving as a consultant pharmacist and as a faculty member for the Mercy Medical Center – North Iowa Palliative Medicine Fellowship.

Links to Resources:

• American Academy of Neuropathy – Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary
• Healthcare Claim Study – Opioids in Peripheral Neuropathy

 How to Claim CE

CE is available for CEimpact members. 

• Click here to claim CPE Credit 
• Click here to claim  CME Credit

Need a membership?

• Join for CPE Credit 
• Join for CME Credit

Learning Objectives: 

1. Select an appropriate first line medication for diabetic neuropathic pain (DNP) based on the 2022 guidelines

2. Describe the treatment effects of the drugs used for DNP in the 2022 guidelines

Dr. Wall is a member of the Janssen Speaker's Bureau. 

Dr. John Swegle reports no actual or potential conflicts of interest associated with this episode.

Continuing Education Information:

0.05 CEU | 0.5 Hrs

ACPE UAN: 0107-0000-22-057-H01-P

Initial release date: 01/03/22

Expiration date: 01/03/2023

Additional CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Two oral therapies for COVID-19 were recently approved. Listen in as we discuss who is eligible to receive them, their efficacy, and what this means for the future of COVID-19 treatment.

Guest:
Patrick Kinn, PharmD, MPH, BCPS
Clinical Pharmacy Specialist - Infectious Disease
University of Iowa Health Care

John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad, Inc

Redeem your CPE or CME credit here!
Pharmacist members
CME

Need a membership?
Join for CPE Credit
Join for CME Credit

References and resources: 

1. Jayk BA, Gomes da Silva MM, Musungaie DB, et al. MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2021 Dec 16:NEJMoa2116044. doi: 10.1056/NEJMoa2116044. Epub ahead of print. PMID: 34914868; PMCID: PMC8693688.
2. PAXLOVID (nirmatrelvir) [Emergency Use Authorization]. U.S. Food and Drug Administration website. Published December 22, 2021. Accessed January 5, 2021. https://www.fda.gov/media/155050/download
3. Liverpool COVID-19 Interactions. https://www.covid19-druginteractions.org/
4. COVID-19 Public Therapeutic Locator. https://healthdata.gov/Health/COVID-19-Public-Therapeutic-Locator/rxn6-qnx8/data

Continuing Education Information:

Learning Objectives: 

1. Identify the eligible population for treatment of COVID-19 with oral therapy
2. Discuss the efficacy of currently available oral therapy treatment options for COVID-19

Dr. Wall is a member of the Janssen Speaker's Bureau. 
Dr. Galdo reports no actual or potential conflicts of interest associated with this episode.
Dr. Kinn reports no actual or potential conflicts of interest associated with this episode.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-056-H01-P
Initial release date: 01/17/22
Expiration date: 01/17/2023
Additional CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram